Patent US3188764A successfully refreshed from Google Patents.
US4034087A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical composition and process of treatment
Assignee: University of Michigan (System)
•
Filing: 1976-01-05
•
Granted: 1977-07-05
•
Expires: 1996-01-05
Abstract
Abstract A process for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc. comprising administering to humans, or domesticated animals, topically and/or systemically a composition comprising a pharmaceutical carrier and at least one active compound selected from the groups, substituted alkyl zanthines, tricyclic antidepressants, organic nitrates, antihypertensives, anti-asthma agents and central nervous system depressants and combinations of certain compounds from specifically named groups of compounds.
Inventors
- 👤 John J. Voorhees
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 10:18
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/16; C07H19/20
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
148 words
A process for treating a proliferative skin disease which comprises administering to the afflicted human or animal a composition containing as its active component at least one of the compounds selected from the group consisting of compounds characterized by the formula: ##STR22## wherein R is halogen, hydrogen, lower alkyl and lower alkoxy; R 2 , R 3 and R 4 taken independently of each other are hydrogen, lower alkoxy or hydroxy-lower alkoxy and provided that R 2 , R 3 and R 4 taken independently of each other represent at least one oxygenated substituent; or R, R 2 , R 3 and R 4 taken as a adjacent pair is methylenedioxy and the optical antipodes thereof, said compounds being in association with a pharmaceutical carrier and present in an amount in the range of about 0.1 to about 10% which is effective to alleviate a proliferative skin disease.
Claim 2
Dependent Claim
148 words
A process for treating a proliferative skin disease which comprises administering to the afflicted human or animal a composition containing as its active component at least one of the compounds selected from the group consisting of compounds characterized by the formula: ##STR22## wherein R is halogen, hydrogen, lower alkyl and lower alkoxy; R 2 , R 3 and R 4 taken independently of each other are hydrogen, lower alkoxy or hydroxy-lower alkoxy and provided that R 2 , R 3 and R 4 taken independently of each other represent at least one oxygenated substituent; or R, R 2 , R 3 and R 4 taken as a adjacent pair is methylenedioxy and the optical antipodes thereof, said compounds being in association with a pharmaceutical carrier and present in an amount in the range of about 0.1 to about 10% which is effective to alleviate a proliferative skin disease.
Claim 3
Dependent Claim
22 words
A process in accordance with claim 1, wherein said active component is administered in conjunction with a permissive dosage of a glucocorticoid.
Claim 4
Dependent Claim
45 words
A process for treating a proliferative skin disease which comprises administering to the afflicted human or animal a composition comprising a pharmaceutical carrier and d,1-4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone in an amount in the range of about 0.1% to about 10% w/v which is effective to alleviate said disease.
Claim 5
Dependent Claim
45 words
A process for treating a proliferative skin disease which comprises administering to the afflicted human or animal a composition comprising a pharmaceutical carrier and d,1-4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone in an amount in the range of about 0.1% to about 10% w/v which is effective to alleviate said disease.
Claim 6
Dependent Claim
21 words
A process in accordance with claim 3 wherein said composition is administered in conjunction with a permissive dosage of a glucocorticoid.
Claim 7
Dependent Claim
165 words
A process for treating a proliferative skin disease which comprises administering to the afflicted human or animal a composition comprising at least two active compounds in association with a pharmaceutical carrier, said compounds being present in an amount in the range of about 0.1% to about 10% w/v which is effective to alleviate a proliferative skin disease, the first of said active compounds having the formula ##STR23## wherein R is halogen, hydrogen, lower alkyl and lower alkoxy; R 2 , R 3 and R 4 taken independently of each other are hydrogen, lower alkoxy or hydroxy-lower alkoxy and provided that R 2 , R 3 , and R 4 taken independently of each other represent at least one oxygenated substituent; R, R 2 , R 3 and R 4 taken as an adjacent pair is methylenedioxy and the optical antipodes thereof, and at least one compound selected from the group consisting of isoproterenol, salbutamol, epinephrine, nor-epinephrine, ephedrine and prostaglandin E 1 and E 2 .
Claim 8
Dependent Claim
165 words
A process for treating a proliferative skin disease which comprises administering to the afflicted human or animal a composition comprising at least two active compounds in association with a pharmaceutical carrier, said compounds being present in an amount in the range of about 0.1% to about 10% w/v which is effective to alleviate a proliferative skin disease, the first of said active compounds having the formula ##STR23## wherein R is halogen, hydrogen, lower alkyl and lower alkoxy; R 2 , R 3 and R 4 taken independently of each other are hydrogen, lower alkoxy or hydroxy-lower alkoxy and provided that R 2 , R 3 , and R 4 taken independently of each other represent at least one oxygenated substituent; R, R 2 , R 3 and R 4 taken as an adjacent pair is methylenedioxy and the optical antipodes thereof, and at least one compound selected from the group consisting of isoproterenol, salbutamol, epinephrine, nor-epinephrine, ephedrine and prostaglandin E 1 and E 2 .
Claim 9
Dependent Claim
21 words
A process in accordacne with claim 5 wherein said first active compound corresponding to the formula in claim 5 is d,1-4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone.
Claim 10
Dependent Claim
177 words
A process for treating a proliferative skin disease which comprises administering to the afflicted human or animal a composition comprising a glucocorticoid in a permissive dose amount and at least two active compounds in association with a pharmaceutical carrier, said compounds being present in an amount in the range of about 0.1% to about 10% w/v which in combination with said glucocorticoid is effective to alleviate a proliferative skin disease, the first of said active compounds having the formula ##STR24## wherein R is halogen, hydrogen, lower alkyl and lower alkoxy; R 2 , R 3 and R 4 taken independently of each other are hydrogen, lower alkoxy or hydroxy-lower alkoxy and provided that R 2 , R 3 and R 4 taken independently of each other represent at least one oxygenated substituent; R, R 2 , R 3 and R 4 taken as an adjacent pair is methylenedioxy and the optical antipodes thereof, and at least one compound selected from the group consisting of isoproterenol, salbutamol, epinephrine, nor-epinephrine, ephedrine and prostaglandin E 1 and E 2 .
Claim 11
Dependent Claim
177 words
A process for treating a proliferative skin disease which comprises administering to the afflicted human or animal a composition comprising a glucocorticoid in a permissive dose amount and at least two active compounds in association with a pharmaceutical carrier, said compounds being present in an amount in the range of about 0.1% to about 10% w/v which in combination with said glucocorticoid is effective to alleviate a proliferative skin disease, the first of said active compounds having the formula ##STR24## wherein R is halogen, hydrogen, lower alkyl and lower alkoxy; R 2 , R 3 and R 4 taken independently of each other are hydrogen, lower alkoxy or hydroxy-lower alkoxy and provided that R 2 , R 3 and R 4 taken independently of each other represent at least one oxygenated substituent; R, R 2 , R 3 and R 4 taken as an adjacent pair is methylenedioxy and the optical antipodes thereof, and at least one compound selected from the group consisting of isoproterenol, salbutamol, epinephrine, nor-epinephrine, ephedrine and prostaglandin E 1 and E 2 .
Claim 12
Dependent Claim
21 words
A process in accordance with claim 7 wherein said first active compound corresponding to the formula in claim 7 is d,1-4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-07-04 | 1981-01-03 | 1981-07-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-07-04 | 1985-01-03 | 1985-07-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-07-04 | 1989-01-03 | 1989-07-05 | $7700.00 | Window Closed / Lapsed |